UK: Should High Stay, For EPO? Actavis And Pharmacia Clash In The High Court

Last Updated: 13 August 2014
Article by Anna Leathly and Glyn Truscott

Mr Justice Arnold in the Patents Court of the High Court of England and Wales (the 'Patents Court') initially refused a request by the patentee, Pharmacia, for a stay of UK revocation proceedings brought by Actavis, pending the outcome of opposition proceedings at the EPO based on three undertakings. When Pharmacia then offered additional undertakings, which "substantially eliminate the commercial uncertainty to which Actavis will be exposed in the UK as a result of a stay", the stay was then granted in a second decision.

These two decisions apply the guidance recently provided by the Court of Appeal of England and Wales in IPCom v HTC, as to when UK proceedings should be stayed pending the outcome of opposition proceedings at the European Patent Office (EPO). Although IPCom v HTC introduced the notion that the default position should be to grant a stay of the UK proceedings, this is another case where the initial request for a stay was refused when all factors were considered.

Staying UK proceedings

Once granted, the validity of a European patent may be challenged centrally at the EPO (in the nine months after grant), and also in each country in which the patent has been validated (at any time). In some countries, such as Germany, national revocation proceedings are stayed automatically while an EPO opposition is pending. However, in the English courts this is determined on a case-by-case basis taking into account all relevant circumstances. Initially in the current case, when all relevant factors were taken into account, the result was finely balanced but the stay was refused.

The relatively low cost of EPO proceedings compared to national proceedings is highlighted in the present case (with estimates of around £1million to £1.8million for each side's costs for first instance proceedings in the English Patents Court, compared with EPO oppositions costing "a fraction of these amounts"), but the potential for such "wasted costs" was outweighed by the longer time that it takes to obtain a final decision at the EPO, and the commercial uncertainty that would be prolonged by a stay.


Pharmacia's patent, EP1536792, relates to sustained release dosage forms of pramipexole suitable for once daily administration for the treatment of Parkinson's disease and restless leg syndrome (patent protection for pramipexole itself having expired). The patent is exclusively licensed to Boehringer Ingelheim GmbH, and will not expire until 2023.

With the intention of launching a generic sustained release form of pramipexole, Actavis commenced revocation proceedings (against the UK patent) in the High Court on 3rd April 2014, having already filed an opposition to the patent at the EPO on 14th October 2013 (which was well before the opposition deadline). Actavis had also applied for a marketing authorisation for a generic sustained release form of pramipexole, which it expects to be granted before June 2015. Despite this clear threat to infringe the patent, Pharmacia had not yet counterclaimed for threatened infringement.

Pharmacia requested a stay of the UK revocation proceedings pending the outcome of the EPO opposition and in doing so offered three undertakings: (a) to seek expedition of the EPO proceedings, (b) not to seek an injunction against Actavis or its customers until the determination of the EPO proceedings, and (c) only to seek damages of 1% of Actavis' net sales during the period from launch until the determination of the EPO proceedings if the patent is held valid both by the EPO and by the English courts. Actavis opposed the stay.

The first decision

The relative timing of the national and EPO proceedings was an important factor in the present decision. Actavis commenced its UK revocation action relatively soon after its opposition was filed at the EPO, and well before the end of the opposition period. The judge, Mr Justice Arnold, estimated that the UK proceedings would take around two years to be resolved (including an appeal), but that even expedited proceedings at the EPO would take at least three years to resolve, and potentially longer.

A delay of at least three years to the UK proceedings would therefore be caused by a stay, if the EPO were to reject the opposition. Of course if the EPO revoked the patent then the UK patent would cease to exist and there would be no resumption of national proceedings.

Pharmacia's view was that the delay in commercial certainty that would be caused by staying the UK action was eliminated by the undertakings not to seek an injunction until the determination of the EPO proceedings and only to seek limited damages during the EPO proceedings (which were estimated at around £189,000 based on selling at 90% of Pharmacia's average price and a market share of 50%). Actavis argued that the undertakings did not mitigate the risk that it would start to market its product and subsequently be restrained from doing so, resulting in damage to its commercial position. Actavis also noted the difficulty of predicting the market five years ahead of time and that there may be an effect from further generic competitors.

Arnold J found the considerations to be finely balanced, but determined that the delay that would be caused by a stay would result in unacceptable commercial uncertainty for Actavis. Arnold J considered that Pharmacia's undertakings did not go quite far enough to eliminate commercial uncertainty for Actavis in the UK if the national proceedings were stayed, even though they allow Actavis the benefit of ensuring that it can get onto the market; the undertakings did not address the uncertainty caused by the prospect that Actavis may be removed from the market by an injunction at a later date, at which point the limited damages referred to in Pharmacia's undertakings would not apply. This, he said, would "have a chilling effect" on Actavis' investment decisions.

So, despite some factors in this case favouring a stay, including the risk of potentially wasted costs arising from the UK proceedings (estimated to total in excess of £2.5million), the stay was refused to reduce commercial uncertainty. Arnold J also notes that refusal of a stay is supported by the possibility that an English decision may promote a settlement and by the public interest in determining the validity of the patent.

The second decision

This was not the end of the story, as a postscript to the first judgment notes that after receiving the judgment in draft, Pharmacia offered two additional undertakings in return for a stay of the UK proceedings. Pharmacia offered (i) not to seek an injunction in the UK against Actavis or its customers in relation to Actavis' sustained release pramipexole product during the life of the patent and (ii) only to seek damages of 1% of Actavis' net sales in the UK during the life of the patent if the patent is ultimately held valid by the EPO and valid and infringed by the English courts. These additional undertakings were enough to tip the balance in favour of a stay, on the basis that the commercial uncertainty to which Actavis will be exposed in the UK as a result of a stay was substantially eliminated.

Practical implications

It is clear from this case that claimants seeking to revoke a UK patent when an EPO opposition is pending, and avoid a stay of the national proceedings, should not delay in starting the national proceedings. Even an estimate of only three years for the conclusion of the proceedings at the EPO was considered to cause unacceptable commercial uncertainty for Actavis. However, if the claimant had delayed its UK action by, say, a year then the timings of the EPO and UK proceedings would start to align and a stay would seem to be more likely.

For patentees wishing to obtain a stay of UK revocation proceedings in favour of the vastly lower cost of opposition proceedings at the EPO, careful consideration must be given to the undertakings that they are prepared to offer, to eliminate the commercial uncertainty that a stay would cause.

Need advice?

For more information, please contact

Carpmaels & Ransford LLP is a leading firm of European patent attorneys based in London. For more information about our firm and our practice, please visit our website at

This briefing note was first published in the IAM IP Newsletter.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.